ArticleAtherosclerosis2007
Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM.
Article in Atherosclerosis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Comprehensive view of macrophage autophagy and its application in cardiovascular diseases.Cell proliferation · 2024Review
- Effectiveness and safety of immunosuppressive regimens used as maintenance therapy in kidney transplantation: The CESIT study.PloS one · 2024Observational
- Development of calciphylaxis in kidney transplant recipients with a functioning graft.Clinical kidney journal · 2022Article
- Roles of mTOR in thoracic aortopathy understood by complex intracellular signaling interactions.PLoS computational biology · 2021Article
- Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice.Journal of nephrology · 2020Article
- Combinatorial therapy of sirolimus and heparin by nanocarrier inhibits restenosis after balloon angioplastyNanomedicine (London, England) · 2020Article
- A role for proteoglycans in vascular disease.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.Journal of the American Society of Nephrology : JASN · 2018Article
- Promoting vascular healing using nanofibrous ticagrelor-eluting stents.International journal of nanomedicine · 2018Article
- Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application.Frontiers in pharmacology · 2018Review
- Potential therapeutic effects of mTOR inhibition in atherosclerosis.British journal of clinical pharmacology · 2016Review
- Rapamycin Inhibits Oxidized Low Density Lipoprotein Uptake in Human Umbilical Vein Endothelial Cells via mTOR/NF-κB/LOX-1 Pathway.PloS one · 2016Article
- RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.The Journal of clinical investigation · 2012Article
- NADPH oxidase-derived reactive oxygen species increases expression of monocyte chemotactic factor genes in cultured adipocytes.The Journal of biological chemistry · 2012Article
- Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.JACC. Cardiovascular interventions · 2011Review
- Polyinosine-polycytidylic acid stimulates versican accumulation in the extracellular matrix promoting monocyte adhesion.American journal of respiratory cell and molecular biology · 2010Article
- Extracellular matrix molecules: potential targets in pharmacotherapy.Pharmacological reviews · 2009Review
- Differential proteoglycan and hyaluronan distribution in calcified aortic valves.Cardiovascular pathology : the official journal of the Society for Cardiovascular PathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution.
Funding
Abstract
Sirolimus (SRL), an inhibitor of human arterial smooth muscle cell (ASMC) proliferation and migration, prevents in-stent restenosis (ISR). Little is known about the effect of SRL on the extracellular matrix (ECM) component, hyaluronan, a key macromolecule in neointimal hyperplasia and inflammation. In this study, we investigated SRL regulation of the synthesis of hyaluronan by cultured human ASMC and the effect of SRL on hyaluronan mediated monocyte adhesion to the ECM. Hyaluronan production on a per cell basis was significantly inhibited by SRL at 4 days and remained so through 10 days. This reduction was correlated with reduced levels of hyaluronan synthase mRNAs while hyaluronan degradation rates were unchanged. Poly I:C, a viral mimetic, caused increased hyaluronan accumulation by ASMC cell layers and this increase was inhibited by SRL. The inhibition was paralleled by a reduction in hyaluronan-dependent monocyte adhesion to the ECM. This study demonstrates that SRL not only regulates the proliferation of ASMC but reduces the production of hyaluronan by these cells. This alteration in ECM composition results in reduced monocyte adhesion to the ECM in cultures of ASMC. Alterations in hyaluronan accumulation may contribute to the inhibition of ISR that is achieved by SRL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.